Literature DB >> 10625496

The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts.

G Datta1, M Chaddha, D W Garber, B H Chung, E M Tytler, N Dashti, W A Bradley, S H Gianturco, G M Anantharamaiah.   

Abstract

Human apolipoprotein E (apo E) consists of two distinct domains, the lipid-associating domain (residues 192-299) and the globular domain (residues 1-191) which contains the LDL receptor (LDLR) binding site (residues 129-169). To test the hypothesis that an arginine-rich apo E receptor binding domain (residues 141-150) is sufficient to enhance low-density lipoprotein (LDL) uptake and clearance when covalently linked to a class A amphipathic helix, a peptide in which the receptor binding domain of human apo E, LRKLRKRLLR (hApoE[141-150]), is linked to 18A, a well-characterized high-affinity lipid-associating peptide (DWLKAFYDKVAEKLKEAF), we synthesized the peptide hApoE[141-150]-18A (hE18A) and its end-protected analogue, Ac-hE18A-NH(2). The importance of positively charged residues and the role of the hydrophobic residues in the receptor binding domain were also studied using four analogues. Ac-LRRLRRRLLR-18A-NH(2) [Ac-hE(R)18A-NH(2)] and Ac-LRKMRKRLMR-18A-NH(2) (Ac-mE18A-NH(2)) contained an extended hydrophobic face, including the receptor binding region. Control peptides, Ac-LRLLRKLKRR-18A-NH(2) [Ac-hE(Sc)18A-NH(2)], had the amino acid residues of the apo E receptor binding domain scrambled to disrupt the extended hydrophobic face, and Ac-RRRRRRRRRR-18A-NH(2) (Ac-R(10)18A-NH(2)) had only positively charged Arg residues as the receptor binding domain. The effect of the dual-domain peptides on the uptake and degradation of human LDL by fibroblasts was determined in murine embryonic fibroblasts (MEF1). LDL internalization was enhanced 3-, 5-, and 7-fold by Ac-mE18A-NH(2), Ac-hE18A-NH(2), and Ac-hE(R)18A-NH(2), respectively, whereas the control peptides had no significant biological activity. All three active peptides increased the level of degradation of LDL by 100%. The LDL binding and internalization to MEF1 cells in the presence of these peptides was not saturable over the LDL concentration range that was studied (1-10 microgram/mL). Furthermore, a similar enhancement of LDL internalization was observed independent of the presence of the LDL receptor-related protein (LRP), LDLR, or both. Pretreatment of cells with heparinase and heparitinase abolished more than 80% of the enhanced peptide-mediated LDL uptake and degradation by cells. We conclude that the dual-domain peptides enhanced LDL uptake and degradation by fibroblasts via a heparan sulfate proteoglycan (HSPG)-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625496     DOI: 10.1021/bi991209w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

1.  Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice.

Authors:  Shaila P Handattu; Geeta Datta; Richard M Epand; Raquel F Epand; Mayakonda N Palgunachari; Vinod K Mishra; Candyce E Monroe; Tamara D Keenum; Manjula Chaddha; G M Anantharamaiah; David W Garber
Journal:  J Lipid Res       Date:  2010-09-14       Impact factor: 5.922

2.  Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.

Authors:  Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Shaila P Handattu; Vinod K Mishra; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-06-23       Impact factor: 5.162

Review 3.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

4.  Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects.

Authors:  Gaurav Nayyar; Shaila P Handattu; Candyce E Monroe; Manjula Chaddha; Geeta Datta; Vinod K Mishra; Tamara D Keenum; Mayakonda N Palgunachari; David W Garber; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2010-10-27       Impact factor: 5.162

Review 5.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

6.  The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.

Authors:  Samantha Giordano-Mooga; Geeta Datta; Paul Wolkowicz; David W Garber; Mayakonda Palgunachari; C Roger White; G M Anantharamaiah
Journal:  Curr Top Pept Protein Res       Date:  2018

7.  Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Authors:  G M Anantharamaiah; Dennis Goldberg
Journal:  Clin Lipidol       Date:  2015-01-01

8.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01

9.  Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.

Authors:  Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-11-02       Impact factor: 5.162

10.  Transduction of rat pancreatic islets with pseudotyped adeno-associated virus vectors.

Authors:  Anthony T Craig; Oksana Gavrilova; Nancy K Dwyer; William Jou; Stephanie Pack; Eric Liu; Klaus Pechhold; Michael Schmidt; Victor J McAlister; John A Chiorini; E Joan Blanchette-Mackie; David M Harlan; Roland A Owens
Journal:  Virol J       Date:  2009-05-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.